Dr. Kurt Krapfenbauer is founder and Vice-president of the European Association for Predictive, Preventive and Personalised Medicine (EPMA). He studied chemistry at the University of Vienna, including four year, Amino Acid Society financed study as a research assistant at the general hospital in Vienna. Subsequently he did his PhD in bio-chemistry at the Ludwig Boltzmann Institute for Radiation Chemistry and Radiation Biology. As a post-doc at Roche Center for Medical Genomics in Basel, Switzerland he continued his work on proteome research. Dr. Krapfenbauer then joined Hoffmann LaRoche (Basel, Switzerland) as a lab head for proteome research and then as a lab head for biomarker research at the Novartis Institute for Biomedical Research. In 2008, he is cofounder of EPMA. He has spoken and published extensively on biomarker research, addressing aspects from biomarker discovery to clinical application of new and innovative diagnostics assays. Since 2008 he is working as biomarker specialist at the Medical University of Vienna in cooperation with the pharmaceutical industry.
The mission of EPMA is to provide the scientific and medical community with speedy and compliant access to clinical results in the field of predictive, preventive & personalised medicine. The paradigm change from delayed interventional to Predictive, Preventive and Personalised Medicine (PPPM) is a leading global challenge in the 21st century. This is a new philosophy of advanced healthcare and the platform for more effective treatments tailored to the person that is considered as the "medicine of the future". This paradigm change can be achieved only by well-coordinated measures focused on solving the accumulating problems in healthcare and reducing the concomitant economical burden that societies across the globe are progressively facing. This task requires novel and creative political regulations and formation of new guidelines to advance current healthcare systems. The overall concept in the field is conducted by the “European Association for Predictive, Preventive and Personalised Medicine” (EPMA) – the “umbrella”-organisation in over 40 countries around Europe and worldwide.